JPWO2022216837A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022216837A5
JPWO2022216837A5 JP2023562568A JP2023562568A JPWO2022216837A5 JP WO2022216837 A5 JPWO2022216837 A5 JP WO2022216837A5 JP 2023562568 A JP2023562568 A JP 2023562568A JP 2023562568 A JP2023562568 A JP 2023562568A JP WO2022216837 A5 JPWO2022216837 A5 JP WO2022216837A5
Authority
JP
Japan
Prior art keywords
cells
natural killer
pharmaceutical combination
population
killer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513958A (ja
JP2024513958A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023691 external-priority patent/WO2022216837A1/en
Publication of JP2024513958A publication Critical patent/JP2024513958A/ja
Publication of JPWO2022216837A5 publication Critical patent/JPWO2022216837A5/ja
Publication of JP2024513958A5 publication Critical patent/JP2024513958A5/ja
Pending legal-status Critical Current

Links

JP2023562568A 2021-04-08 2022-04-06 Ｎｋ細胞およびｅｇｆｒ標的抗体を用いた癌治療 Pending JP2024513958A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172423P 2021-04-08 2021-04-08
US63/172,423 2021-04-08
US202163290361P 2021-12-16 2021-12-16
US63/290,361 2021-12-16
PCT/US2022/023691 WO2022216837A1 (en) 2021-04-08 2022-04-06 Treatment of cancer with nk cells and an egfr targeted antibody

Publications (3)

Publication Number Publication Date
JP2024513958A JP2024513958A (ja) 2024-03-27
JPWO2022216837A5 true JPWO2022216837A5 (https=) 2025-04-14
JP2024513958A5 JP2024513958A5 (https=) 2025-04-14

Family

ID=83546563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562568A Pending JP2024513958A (ja) 2021-04-08 2022-04-06 Ｎｋ細胞およびｅｇｆｒ標的抗体を用いた癌治療

Country Status (7)

Country Link
US (1) US20240366664A1 (https=)
EP (1) EP4319772A4 (https=)
JP (1) JP2024513958A (https=)
KR (1) KR20240024049A (https=)
CN (1) CN118103048A (https=)
AU (1) AU2022253889A1 (https=)
WO (1) WO2022216837A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
US12116417B2 (en) 2017-11-14 2024-10-15 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
MY199770A (en) 2018-11-14 2023-11-22 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t cells
KR20240131924A (ko) * 2023-02-24 2024-09-02 주식회사 엔케이맥스 항-EGFR 항체의약품과 병용하는 자연살해세포의 TKIs 내성 비소세포폐암 치료방법
AU2024244976A1 (en) * 2023-03-24 2025-09-25 Board Of Regents, The University Of Texas System Engineered natural killer cells with enhanced antitumor memory responses
WO2025191137A1 (en) * 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124766A2 (ko) * 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
WO2019179390A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/egfr antibody molecules
EP4474391A3 (en) * 2018-05-14 2025-02-26 Indapta Therapeutics, Inc. Subsets of human natural killer cells with enhanced antibody-directed immune responses

Similar Documents

Publication Publication Date Title
Rohaan et al. Adoptive cellular therapies: the current landscape
Bordignon et al. Cell therapy: achievements and perspectives
Tomuleasa et al. Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia
Tsang et al. Indefinite mouse heart allograft survival in recipient treated with CD4+ CD25+ regulatory T cells with indirect allospecificity and short term immunosuppression
Locatelli et al. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies
van Ostaijen-ten Dam et al. Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential
JP7410856B2 (ja) ドナー改変細胞の選択のための調節可能スイッチ
JP2007527245A (ja) レギュラトリーｔ細胞並びに免疫療法及び自己免疫応答の抑制におけるそれらの使用
KR20140092298A (ko) 항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도
JPH09510456A (ja) 同種リンパ球による癌の免疫療法
JP2022522231A (ja) 抗ｂｃｍａ ｃａｒ ｔ細胞の製造
CN103282047A (zh) 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
Van Caeneghem et al. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities
WO2012146702A1 (en) Methods for preparing accessory cells and uses thereof for preparing activated nk cells
JP2025514745A (ja) 血液悪性腫瘍の治療のための同種ｔ細胞
JP2025514745A5 (https=)
Maeda Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide
JPWO2022216837A5 (https=)
CN113454209A (zh) 通用型双阴性t细胞的制备和治疗用途
Soiffer Donor lymphocyte infusions for acute myeloid leukaemia
Caruso et al. NK cells as adoptive cellular therapy for hematological malignancies: advantages and hurdles
Gu et al. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: from the lab to the clinic
JPWO2023278811A5 (https=)
Su et al. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells
JPWO2022216831A5 (https=)